$AIMAug 12, 2026, 12:44 PMAI processed
AIM CEO urges military biodefense use of Ampligen as broad-spectrum antiviral
AI Summary
AIM ImmunoTech CEO Thomas K. Equels published an op-ed arguing that biodefense should be treated as military force protection and highlighted Ampligen (rintatolimod) as a candidate broad‐spectrum prophylactic/early‐onset antiviral. The company cites government‐funded preclinical work (USAMRIID, reported in Antiviral Research) showing a rintatolimod‐treated mouse cohort had 100% survival vs 100% mortality in controls for a lethal Ebola model and says it is seeking government support for further evaluation and potential force‐protection pathways.
Positives
- CEO publicity raises visibility for Ampligen as a biodefense/military force‑protection candidate
- Cites government‑funded USAMRIID preclinical data (reported in Antiviral Research) showing 100% survival in a treated mouse cohort vs 100% mortality in controls in a lethal Ebola model
- Company is actively seeking government support to pursue further studies and evaluation for prophylactic/early‑onset countermeasure use
Negatives
- Results cited are preclinical (mouse) and do not demonstrate safety or efficacy in humans
- No new clinical trials, regulatory approvals, procurements, or stockpiling commitments were announced
- Company statements are forward‑looking and subject to significant testing, regulatory and funding risks